Aclaris Therapeutics Inc (NASDAQ:ACRS) was up 6.7% during mid-day trading on Thursday . The company traded as high as $1.14 and last traded at $1.11, approximately 203,400 shares changed hands during trading. A decline of 71% from the average daily volume of 698,307 shares. The stock had previously closed at $1.04.
A number of analysts recently issued reports on ACRS shares. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 27th. ValuEngine upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 24th. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of Aclaris Therapeutics in a research note on Thursday, January 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $6.67.
The company has a market cap of $43.19 million, a PE ratio of -0.28 and a beta of 0.88. The stock’s 50 day simple moving average is $1.14 and its two-hundred day simple moving average is $1.50.
About Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Recommended Story: Why is the Consumer Price Index (CPI) important?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.